FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
Tag: Dexolve
Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)
Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration
Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
Remdesivir, an investigational broad-spectrum antiviral agent, formulated with sulfobutyl beta-cyclodextrin, has shown in vitro activity against SARSCoV-2. Currently, remdesivir is
Combined therapy (remdesivir, dexamethasone and monoclonal antibodies) for the treatment of President Trump
Science News reported on October 5, 2020 the opinion of Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital
Final Results of NIAID’s Trial Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19
— Final Day 29 Data Show Superior Efficacy of Veklury Compared with Placebo in Hospitalized Patients Receiving Standard of Care
Már Magyarországnak is van koronavírus elleni gyógyszere
Már gőzerővel gyártják Magyarországon a koronavírus elleni egyik leghatékonyabb gyógyszert – erősítette meg a Richter az Index értesüléseit. A RICHTER
Inclusion complex of chrysin with sulfobutyl ether-β-cyclodextrin
The work of Kulkarni and Belgamvar [1] demonstrates the impact of sulfobutyl ether-β-cyclodextrin (SBE-β-CD) complexation on the solubility, dissolution and
Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States
Since the COVID-19 pandemic began, Gilead has worked diligently to ramp up production and rapidly expand the supply of our
UofA lab uncovers new mechanism of action against SARS-CoV-2 by antiviral drug remdesivir
News Release on 23-Sep-2020 on Eurokalert Researchers at the University of Alberta have discovered a novel, second mechanism of action
Marinus Awarded BARDA Contract to Develop SBECD-enabled Ganaxolone for Treatment of Refractory Status Epilepticus
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it has